中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
1期
85-89
,共5页
袁莲芳%高影%刘利宁%赵志敏%李毓新
袁蓮芳%高影%劉利寧%趙誌敏%李毓新
원련방%고영%류리저%조지민%리육신
脉血康胶囊%脑卒中%认知障碍%痴呆,血管性
脈血康膠囊%腦卒中%認知障礙%癡呆,血管性
맥혈강효낭%뇌졸중%인지장애%치태,혈관성
Maixuekang capsules%Stroke%Cognition disorders%Dementia,vascular
目的 观察脉血康胶囊对脑卒中后伴不同程度血管性认知功能障碍(vCI)患者认知功能及非认知功能的干预效果.方法 选取2010年1月至2012年8月在西安医学院第二附属医院神经内科住院并出院后于门诊复诊的脑卒中后伴不同程度VCI患者148例,其中血管性痴呆(VD)患者71例,非痴呆性认知功能障碍(VCIND)患者77例,根据治疗方法将其分为VD治疗组(36例)、VD对照组(35例)、VCIND治疗组(38例)和VCIND对照组(39例).所有患者均进行认知功能训练、运动功能及日常生活活动能力(ADL)训练.VD治疗组与VCIND治疗组在上述康复训练基础上口服脉血康胶囊,每次4粒,每天3次,连续90 d.采用简易智能状态量表(MMSE)评估患者的认知功能.采用简化Fugl-Meyer量表、Barthel 指数评价患者非认知功能.分别比较VD治疗组与VD对照组、VCIND治疗组与VCIND对照组治疗前、治疗后45 d、治疗后90 d的认知功能和非认知功能评分,同时记录药物的不良反应.结果 ①治疗后90 d,VD治疗组记忆力和MMSE总分[(5.43±0.30)分、(21.0±3.1)分]高于治疗前[(4.85±0.76)分、(17.1±1.6)分]和VD对照组[(5.03±0.49)分、(18.4±1.9)分],差异均有统计学意义(均P＜0.05);治疗后90d,VCIND治疗组定向力、记忆力、注意力和计算力、语言能力和MMSE总分[(9.4±0.7)分、(6.94±0.28)分、(4.5±0.4)分、(6.9±0.6)分、(22.3±2.6)分]高于治疗前[(7.8±0.8)分、(5.99±0.66)分、(3.7±0.7)分、(4.2±0.9)分、(18.5±1.8)分]和VCIND对照组[(8.5±0.9)分、(6.33±0.21)分、(4.0±0.6)分、(5.2±0.6)分、(19.2±1.9)分],差异均有统计学意义(均P＜0.05).②VD治疗组治疗后45 d和治疗后90 d时Fugl-Meyer评分高于VD对照组[(45.8±5.8)分比(52.5±6.1)分比(39.7±3.4)分比(46.4±5.9)分],VCIND治疗组治疗后45 d和治疗后90 d时Fugl-Meyer评分高于VCIND对照组[(50.8±4.9)分比(46.6±2.3)分、(64.2±7.3)分比(53.5±6.8)分],差异均有统计学意义(均P ＜0.05);VD治疗组治疗后90 d时Barthel指数高于VD对照组[(37.5±2.1)分比(32.9±4.0)分],VCIND治疗组治疗后90 d时Baahel指数高于VCIND对照组[(69.4±4.6)比(56.3±6.6)分],差异均有统计学意义(均P＜0.05).③VD治疗组1例发生轻度的胃肠道不适,其余患者未见明显不良反应.结论 脉血康胶囊与康复训练联合治疗脑卒中后伴不同程度VCI患者,可促进患者认知功能、运动功能和ADL能力的改善,提高患者的康复效果.
目的 觀察脈血康膠囊對腦卒中後伴不同程度血管性認知功能障礙(vCI)患者認知功能及非認知功能的榦預效果.方法 選取2010年1月至2012年8月在西安醫學院第二附屬醫院神經內科住院併齣院後于門診複診的腦卒中後伴不同程度VCI患者148例,其中血管性癡呆(VD)患者71例,非癡呆性認知功能障礙(VCIND)患者77例,根據治療方法將其分為VD治療組(36例)、VD對照組(35例)、VCIND治療組(38例)和VCIND對照組(39例).所有患者均進行認知功能訓練、運動功能及日常生活活動能力(ADL)訓練.VD治療組與VCIND治療組在上述康複訓練基礎上口服脈血康膠囊,每次4粒,每天3次,連續90 d.採用簡易智能狀態量錶(MMSE)評估患者的認知功能.採用簡化Fugl-Meyer量錶、Barthel 指數評價患者非認知功能.分彆比較VD治療組與VD對照組、VCIND治療組與VCIND對照組治療前、治療後45 d、治療後90 d的認知功能和非認知功能評分,同時記錄藥物的不良反應.結果 ①治療後90 d,VD治療組記憶力和MMSE總分[(5.43±0.30)分、(21.0±3.1)分]高于治療前[(4.85±0.76)分、(17.1±1.6)分]和VD對照組[(5.03±0.49)分、(18.4±1.9)分],差異均有統計學意義(均P＜0.05);治療後90d,VCIND治療組定嚮力、記憶力、註意力和計算力、語言能力和MMSE總分[(9.4±0.7)分、(6.94±0.28)分、(4.5±0.4)分、(6.9±0.6)分、(22.3±2.6)分]高于治療前[(7.8±0.8)分、(5.99±0.66)分、(3.7±0.7)分、(4.2±0.9)分、(18.5±1.8)分]和VCIND對照組[(8.5±0.9)分、(6.33±0.21)分、(4.0±0.6)分、(5.2±0.6)分、(19.2±1.9)分],差異均有統計學意義(均P＜0.05).②VD治療組治療後45 d和治療後90 d時Fugl-Meyer評分高于VD對照組[(45.8±5.8)分比(52.5±6.1)分比(39.7±3.4)分比(46.4±5.9)分],VCIND治療組治療後45 d和治療後90 d時Fugl-Meyer評分高于VCIND對照組[(50.8±4.9)分比(46.6±2.3)分、(64.2±7.3)分比(53.5±6.8)分],差異均有統計學意義(均P ＜0.05);VD治療組治療後90 d時Barthel指數高于VD對照組[(37.5±2.1)分比(32.9±4.0)分],VCIND治療組治療後90 d時Baahel指數高于VCIND對照組[(69.4±4.6)比(56.3±6.6)分],差異均有統計學意義(均P＜0.05).③VD治療組1例髮生輕度的胃腸道不適,其餘患者未見明顯不良反應.結論 脈血康膠囊與康複訓練聯閤治療腦卒中後伴不同程度VCI患者,可促進患者認知功能、運動功能和ADL能力的改善,提高患者的康複效果.
목적 관찰맥혈강효낭대뇌졸중후반불동정도혈관성인지공능장애(vCI)환자인지공능급비인지공능적간예효과.방법 선취2010년1월지2012년8월재서안의학원제이부속의원신경내과주원병출원후우문진복진적뇌졸중후반불동정도VCI환자148례,기중혈관성치태(VD)환자71례,비치태성인지공능장애(VCIND)환자77례,근거치료방법장기분위VD치료조(36례)、VD대조조(35례)、VCIND치료조(38례)화VCIND대조조(39례).소유환자균진행인지공능훈련、운동공능급일상생활활동능력(ADL)훈련.VD치료조여VCIND치료조재상술강복훈련기출상구복맥혈강효낭,매차4립,매천3차,련속90 d.채용간역지능상태량표(MMSE)평고환자적인지공능.채용간화Fugl-Meyer량표、Barthel 지수평개환자비인지공능.분별비교VD치료조여VD대조조、VCIND치료조여VCIND대조조치료전、치료후45 d、치료후90 d적인지공능화비인지공능평분,동시기록약물적불량반응.결과 ①치료후90 d,VD치료조기억력화MMSE총분[(5.43±0.30)분、(21.0±3.1)분]고우치료전[(4.85±0.76)분、(17.1±1.6)분]화VD대조조[(5.03±0.49)분、(18.4±1.9)분],차이균유통계학의의(균P＜0.05);치료후90d,VCIND치료조정향력、기억력、주의력화계산력、어언능력화MMSE총분[(9.4±0.7)분、(6.94±0.28)분、(4.5±0.4)분、(6.9±0.6)분、(22.3±2.6)분]고우치료전[(7.8±0.8)분、(5.99±0.66)분、(3.7±0.7)분、(4.2±0.9)분、(18.5±1.8)분]화VCIND대조조[(8.5±0.9)분、(6.33±0.21)분、(4.0±0.6)분、(5.2±0.6)분、(19.2±1.9)분],차이균유통계학의의(균P＜0.05).②VD치료조치료후45 d화치료후90 d시Fugl-Meyer평분고우VD대조조[(45.8±5.8)분비(52.5±6.1)분비(39.7±3.4)분비(46.4±5.9)분],VCIND치료조치료후45 d화치료후90 d시Fugl-Meyer평분고우VCIND대조조[(50.8±4.9)분비(46.6±2.3)분、(64.2±7.3)분비(53.5±6.8)분],차이균유통계학의의(균P ＜0.05);VD치료조치료후90 d시Barthel지수고우VD대조조[(37.5±2.1)분비(32.9±4.0)분],VCIND치료조치료후90 d시Baahel지수고우VCIND대조조[(69.4±4.6)비(56.3±6.6)분],차이균유통계학의의(균P＜0.05).③VD치료조1례발생경도적위장도불괄,기여환자미견명현불량반응.결론 맥혈강효낭여강복훈련연합치료뇌졸중후반불동정도VCI환자,가촉진환자인지공능、운동공능화ADL능력적개선,제고환자적강복효과.
Objective To observe the nterventional efficacy of maixuekang capsules on cognitive and non-cognitive functions in patients withdifferent degrees of vascular cognitive impairment after stroke.Methods There were 148 cases,including 71 cases of vascular dementia (VD) and non dementia (VCIND),and 77 cases of patients with impaired cognitive function.The patients were divided into VD treatment group (36 cases),VD control group (35 cases),VCIND treatment group (38 cases) and VCIND group (39 cases).All patients had cognitive function training,motor function and daily life (ADL) training.VD treatment group was treated on the basis of rehabilitation training plus oral vein blood kang capsule.Simple intelligent state scale (MMSE) was usedto assess the patient's cognitive function.Results ①90 days after treatment,memory and MMSE scorein VD treatment group [(5.43 ± 0.30),(21.0 ± 3.1)points] were higher than those before treatment[(4.85 ± 0.76),(17.1 ± 1.6) points] (P ＜ 0.05) ; 90 d after treatment,in directional force VCIND treatment group,memory,attention and computing power,language ability and MMSE score [(9.4 ± 0.7),(6.94 ± 0.28),(4.5 ± 0.4),(6.9 ± 0.6),(22.3 ± 2.6) points] were higher than those before therapy [(7.8 ± 0.8),(5.99 ± 0.66),(3.7±0.7),(4.2 ±0.9),(18.5 ± 1.8)points] and those in the VCIND control group[(8.5 ±0.9),(6.33 ± 0.21),(4.0 ± 0.6),(5.2 ± 0.6),(19.2 ± 1.9) points] ; the difference was statistically significant (P ＜ 0.05).② In VD treatment group,45 d and 90 d after treatment,Fugl-Meyer score was higher than that in VD control group [(45.8 ± 5.8),(52.5 ± 6.1) than (39.7 ± 3.4),(46.4 ± 5.9)] and VCIND treatment group ; the difference had statistical significance (P ＜ 0.05).③ In VD treatment group,1 case had mild gastrointestinal discomfort.Conclusion Vein blood kang capsule combined with rehabilitation training can improvethe cognitive function,the motor function and ADL ability.
